By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD255-Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease, familial hypercholesterolemia
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:11 – 6:07
Why familial hypercholesterolemia (FH) matters: prevalence, stakes, and episode roadmap
Peter Attia introduces John Kastelein and frames FH as an underrecognized but common hereditary driver of cardiovascular risk. He previews the conversation’s arc: FH definition and care, the troubled history of CETP inhibitors, and how CETP/APOE biology may connect to Alzheimer’s disease.
- •Peter explains why cardiovascular disease education is urgent given its global mortality burden
- •FH is positioned as a practical entry point to understand lipid-lowering therapeutics for broad ASCVD risk reduction
- •Peter previews CETP inhibitors’ history and why the newest candidate could be different
- •Peter flags a major theme: the APOE gene vs apoE protein and why APOE4 elevates Alzheimer’s and cardiovascular risk
- 6:07 – 7:25
Kastelein’s origin story: building large-scale FH detection in the Netherlands
John Kastelein recounts his training in Vancouver and returning to Amsterdam to start a lipid clinic where FH dominated referrals. He describes how Dutch population structure helped justify a government-funded national effort to actively find FH patients.
- •John explains why FH referrals comprised a large share of his early lipid-clinic patients
- •He notes limited population movement and regional consanguinity contributing to clustering
- •A large government grant enabled active case-finding efforts
- •John recalls severe early MIs and high mortality in untreated young adults with very high lifelong LDL
- 7:25 – 9:38
What FH looks like clinically: inheritance, early onset, and physical signs
John defines FH as an autosomal dominant, highly penetrant disorder with early-life onset. He describes characteristic physical findings and why the coronary plaques in FH can be especially lethal.
- •FH is autosomal dominant and nearly fully penetrant when mutations are robust
- •Disease begins early; John describes pediatric experience with thousands of children
- •Physical stigmata include tendon xanthomas (hands/Achilles), arcus cornealis, and xanthelasmata
- •John emphasizes FH plaques are often cholesterol-rich and proximal, raising risk of sudden death when ruptured
- 9:38 – 15:38
Phenotype vs genotype: how FH is diagnosed and why adults are harder than children
Peter and John clarify how phenotype-based diagnosis relies on family history and an isolated LDL elevation while excluding secondary causes. John explains why his group leaned on pediatric cases to validate genetic testing and why mutation detection rates differ between children and adults.
- •John outlines clinical diagnosis: family history of premature CAD plus isolated high LDL and affected first-degree relatives
- •Peter highlights the need to exclude secondary causes (e.g., diabetes, thyroid, renal disease) in adults
- •John explains children are a diagnostic ‘linchpin’ because secondary causes are rare in pediatrics
- •In a rigorously defined pediatric cohort, John reports finding mutations in ~95% after deep sequencing, versus much lower detection rates in adult cohorts
- 15:38 – 19:25
Mechanisms behind FH genes: LDL receptor, ApoB binding, and PCSK9 gain-of-function
John gives a simple mechanistic model of how common FH-causing genes converge on impaired hepatic clearance of LDL particles. Peter reinforces the concept with an analogy to make receptor–ligand biology intuitive.
- •John explains LDL clearance depends on ApoB binding to the hepatic LDL receptor and internalization
- •PCSK9 regulates LDL receptor abundance by promoting receptor degradation
- •Mutations in ApoB binding domains, LDL receptor dysfunction, or PCSK9 gain-of-function can all reduce effective LDL clearance
- •Peter offers a ‘baseball/mit’ analogy to illustrate how different mutations produce the same elevated LDL phenotype
- 19:25 – 22:10
Beyond classic FH: plant sterols, ABCG5/8, and why advanced clinics see overlaps
Peter raises cases suggestive of ABCG5/8-related sitosterolemia-like biology. John agrees and explains newer evidence that sitosterolemia is more common than previously thought and that heterozygous ABCG5/8 loss-of-function can elevate plant sterols and mimic FH-like presentations.
- •Peter describes very high sitosterol/campesterol as a clue to ABCG5/8 involvement and a rationale for ezetimibe use
- •John notes historical underestimation of sitosterolemia prevalence and newer estimates suggesting it’s more common
- •John explains heterozygous ABCG5/8 loss-of-function can also raise plant sterols
- •Both discuss why these conditions may co-occur and be encountered in specialized lipid practices
- 22:10 – 30:01
Why cholesterol deposits show up in tendons and eyes: xanthomas, arcus, and clinical pattern-recognition
John discusses theories for why cholesterol deposits appear in high-motion tissues and shares memorable examples from practice. He also underscores the value of careful observation for opportunistic detection.
- •John links tendon xanthomas to frequently used tendons with macrophage/monocyte presence that can store LDL cholesterol
- •Common sites include extensor tendons of the hands and the Achilles; John describes rarer locations he has seen
- •Arcus cornealis is described as a corneal (not lens) cholesterol deposit; eyelid deposits are also noted
- •John shares an anecdote of identifying FH by noticing arcus during a flight
- 30:01 – 34:16
FH diagnostic criteria and pediatric treatment thresholds: Dutch Lipid Clinic scoring and early statins
John compares FH diagnostic frameworks and argues the Dutch Lipid Clinic criteria perform best in predicting mutation-positive FH. He explains how scoring drives clinical decisions, including initiating treatment in childhood for definite FH.
- •John names multiple diagnostic systems (Simon Broome, WHO, Dutch Lipid Clinic) and states the Dutch criteria outperform others in prediction
- •Dutch Lipid Clinic scoring assigns points for family history, physical findings, LDL levels, and strongly for a confirmed mutation
- •A mutation contributes heavily to the score and helps classify ‘definite’ vs ‘probable/possible’ FH
- •John states that in their national approach, definite FH leads to treatment starting as early as age six
- 34:16 – 41:08
Who ‘escapes’ FH complications and why: the rare resistant phenotype
John estimates a small subset of FH patients show no clinical or imaging signs of disease despite lifelong high LDL. He discusses patterns and hypotheses for why, while emphasizing the mechanism remains unknown.
- •John estimates ~5% of FH patients appear free of disease signs (including imaging and physical stigmata) despite high LDL
- •He notes most of these resistant cases are women, and that men rarely show this pattern
- •John observes common traits: very high HDL, non-smoking, thin/active, and rare diabetes
- •He states extensive efforts have not identified a definitive biological explanation for LDL resistance in these individuals
- 41:08 – 49:16
Treating FH across the lifespan: children vs adults, targets, and modern combination therapy
John outlines pediatric management (lifestyle support plus early statins) and describes how adult care becomes more aggressive with multiple drug classes. The discussion covers statin choice, conservative LDL targets in kids, and differences in tolerability.
- •John describes pediatric focus on lifestyle support but emphasizes it does not replace medication for FH
- •He describes starting statins in childhood, noting earlier preference for pravastatin based on trial evidence of carotid IMT benefit
- •Ezetimibe is added in pediatric care; John notes pediatric LDL targets are often conservative and debated
- •In adults transitioning at ~18, John describes escalating to intensive regimens including PCSK9 monoclonals, inclisiran, and in homozygous FH adding evinacumab
- 49:16 – 52:46
Severe heterozygous and homozygous FH: when triple therapy isn’t enough and the role of apheresis/evinacumab
John explains why a subset of heterozygous FH patients remain difficult to treat even with intensive combinations. He contrasts this with advances in homozygous FH management and discusses how newer therapies may reduce reliance on LDL apheresis.
- •John describes ‘severe heterozygous FH’ where even statin + ezetimibe + PCSK9 therapy may not achieve low LDL
- •He links treatment difficulty partly to very high baseline LDL (e.g., starting above ~300) and the math of percentage reductions
- •LDL apheresis is discussed as an option, including experience in very young homozygous FH patients
- •John describes evinacumab as a major ‘rescue’ therapy and notes current IV dosing frequency while mentioning work toward subcutaneous formulations
- 52:46 – 55:47
LDL causality debates: FH as a natural experiment and why exceptions don’t refute the rule
Peter challenges claims that LDL isn’t causal for ASCVD except in metabolic illness. John argues FH demonstrates LDL’s causal role, and both compare outliers in FH to outliers in smoking and lung cancer.
- •Peter raises claims that high LDL may be harmless in metabolically healthy people; John rejects this based on FH experience
- •John emphasizes monogenic LDL elevation in FH leads to premature death when untreated, supporting causality
- •John explains genetic and environmental modifiers can affect expression without negating causation
- •Peter uses the smoking/lung cancer analogy to illustrate why exceptions don’t disprove causal relationships
- 55:47 – 1:13:04
CETP inhibitors: biology, evolutionary framing, and the ‘sordid history’ of drug failures
John explains CETP function and why it was an attractive target, then walks through major CETP inhibitor trials and what went wrong—especially torcetrapib’s off-target blood-pressure effects. He also describes how dalcetrapib’s failure undermined the HDL hypothesis and how anacetrapib validated LDL-lowering as the driver of benefit.
- •John explains CETP transfers cholesterol esters from HDL to LDL and why this may have been advantageous evolutionarily
- •He recounts torcetrapib’s phase 2 blood pressure signal, the decision to proceed anyway, and discovery of off-target adrenal/endothelin effects
- •He describes dalcetrapib as raising HDL without LDL/ApoB change and showing no outcome benefit, helping end the HDL hypothesis
- •He explains anacetrapib’s modest LDL lowering produced a modest MACE reduction consistent with LDL-driven benefit
- 1:13:04 – 1:15:01
Obicetrapib: discovery at Mitsubishi, potency, phase 2 results, and the phase 3 program
John describes how he identified TA-8995’s potency from early data and the rationale for developing it as a highly potent CETP inhibitor that meaningfully lowers LDL/ApoB. Peter and John review phase 3 trials, design choices to ensure higher baseline LDL, and early safety/tolerability observations.
- •John recounts seeing strong phase 1 potency (LDL lowering at very low dose) and near-complete CETP inhibition at the 10 mg dose
- •He reports phase 2 findings of large LDL reductions on top of statins alongside large HDL increases, while emphasizing LDL/ApoB are the key outcome drivers
- •John outlines phase 3 trials (Broadway in ASCVD, Brooklyn in heterozygous FH, and Prevail as a large outcomes trial) and notes event adjudication even when not powered for MACE
- •They discuss trial design choices: baseline LDL targets around ~100 in the outcomes trial and exclusions below guideline thresholds; John reports no identified drug-related side effects so far
- 1:15:01 – 1:41:41
Unexpected metabolic signals: diabetes risk reduction, septicemia protection, and Lp(a) lowering
John expands beyond ASCVD to discuss observed and hypothesized benefits of CETP inhibition on diabetes and septicemia, and he reports substantial Lp(a) lowering seen with obicetrapib. Peter probes mechanisms and emphasizes what remains unknown and what must still be proven clinically.
- •John argues strong CETP inhibition shifts lipoprotein metabolism, increases ApoA1 production, and may improve cholesterol efflux dynamics
- •He cites outcome-trial observations across CETP inhibitors showing lower new-onset type 2 diabetes rates in treatment arms and links this to protecting pancreatic beta cells from lipotoxicity
- •John describes human genetic evidence suggesting CETP loss-of-function is protective in septicemia, potentially via HDL acting as an endotoxin ‘sink’ during infection
- •John reports obicetrapib lowered Lp(a) substantially in a published trial and notes mechanistic uncertainty while highlighting planned isotope studies to investigate
- 1:41:41 – 1:51:53
CETP, APOE4, and brain cholesterol handling: a proposed Alzheimer’s mechanism and a CSF biomarker trial
John explains why APOE4 increases Alzheimer’s risk by impairing cholesterol transport/clearance in the brain, leading to harmful sterol oxidation and inflammation. He proposes that raising ApoA1 (which can cross the blood-brain barrier) via CETP inhibition could compensate for APOE4 dysfunction, and he describes a biomarker-driven trial using cerebrospinal fluid sampling.
- •John describes APOE4 as a poor cholesterol acceptor and transporter in the brain, enabling sterol accumulation and oxysterol-driven inflammation and apoptosis
- •He outlines normal brain cholesterol disposal via conversion to 24-hydroxycholesterol and export across the blood-brain barrier
- •John proposes ApoA1 can cross the blood-brain barrier and potentially substitute for APOE4 dysfunction if circulating ApoA1 rises enough
- •He describes an Amsterdam single-center trial in early Alzheimer’s/MCI measuring blood and CSF biomarkers (including markers of cholesterol synthesis and removal) over months to test mechanistic signals
- 1:51:53 – 2:04:17
APOE4 and cardiovascular disease: remnants, LDL receptor downregulation, and residual risk beyond ApoB
John explains APOE4’s association with higher LDL through enhanced remnant clearance that downregulates LDL receptors, indirectly raising LDL. Peter and John discuss whether APOE4’s cardiovascular risk is fully captured by ApoB or may include additional inflammatory effects.
- •John explains ApoE is carried on VLDL and remnant particles (not LDL) and that ApoE4’s stronger LDL receptor binding accelerates remnant uptake
- •He describes the paradoxical downstream consequence: hepatic LDL receptor downregulation leading to higher LDL levels
- •They discuss inflammatory associations with APOE4 and the debate about whether ApoB normalization eliminates risk differences
- •John suggests APOE4 may carry additional risk properties not fully removed by ApoB lowering, while Peter proposes risk gaps may widen under metabolic stress
